Cancer Research UK logo.
SearchDonate
  • Search

A study adding radiotherapy and radionuclide therapy to hormone therapy to slow the spread of prostate cancer (ADRRAD)

Overview

Cancer types:

Cancer spread to the bone, Prostate cancer, Secondary cancers

Status:

Results

Phase:

Phase 1/2

Details

This study added external radiotherapy and radium 223 to hormone therapy to stop prostate cancer from spreading further in the bones. It was open to men whose prostate cancer had already spread to the bones when diagnosed.

This study was open for people to join between 2016 and 2019. The team published the results in 2021.

Recruitment start: 1 February 2016

Recruitment end: 29 April 2019

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Joe O’Sullivan

Supported by

Bayer

Belfast Health & Social Care Trust

Experimental Cancer Medicine Centre (ECMC)

Movember Foundation

Prostate Cancer UK

Queen's University Belfast

Friends of the Cancer Centre

University of Manchester

Last reviewed: 1 November 2023

CRUK internal database number: 13917

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.